Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04537975
Recruitment Status : Withdrawn (Withdrawn (Study was withdrawn by Sponsor because of change in regulatory strategy.))
First Posted : September 3, 2020
Last Update Posted : December 14, 2020
Sponsor:
Information provided by (Responsible Party):
SeaStar Medical

Brief Summary:
The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19 infections .

Condition or disease Intervention/treatment Phase
Continuous Renal Replacement Therapy Pulmonary Edema COVID-19 Device: C2Rx Other: Standard of Care (SOC) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Clinical Trial of CLR2.0 Hemofiltration Treatment (C2Rx) in Severe or Critically Ill Adults With COVID-19 Infection
Estimated Study Start Date : September 15, 2020
Estimated Primary Completion Date : November 15, 2020
Estimated Study Completion Date : January 15, 2021

Arm Intervention/treatment
Active Comparator: C2Rx
Hemofiltration device
Device: C2Rx
Hemofiltration

Active Comparator: Standard of Care (SOC)
Standard of Care based on protocol inclusion/exclusion criteria
Other: Standard of Care (SOC)
Standard of care that excludes any protocol restrictions.




Primary Outcome Measures :
  1. Pulmonary Oxygenation Function [ Time Frame: Up to 72 hours ]
    Change in patient Arterial Oxygen Partial Pressure (PaO2)/Fractional Inspired Oxygen (FiO2) Ratio


Secondary Outcome Measures :
  1. Pulmonary Compliance of Respiratory System (CRS) [ Time Frame: Up to 96 hours ]
    Change in patient oxygenation

  2. Survival [ Time Frame: 30 days and 60 days ]
    Change in the total number of patients that survived

  3. Hospital Costs 1 [ Time Frame: Out to 60 days ]
    Change in Hospital Utilization of ventilators (days)

  4. Cardiovascular Vasoactive-Inotropic Score (VIS) [ Time Frame: Up to 96 hours ]
    Change in score based on the calculation of the following medications used: dopamine dose (µg/kg/min) + dobutamine dose (µg/kg/min) + 100 x adrenaline dose (µg/kg/min) + 100 x noradrenaline dose (µg/kg/min) + 10 x milrinone dose (µg/kg/min) + 10.000 x vasopressin dose (U/kg/min)

  5. Hospital Costs 2 [ Time Frame: Out to 60 days ]
    Change in Hospital Utilization of vasopressor medication (days without use)

  6. Hospital Costs 3 [ Time Frame: Out to 60 days ]
    Change in Hospital Utilization of Intensive Care Unit (ICU) Hospital free days

  7. Hospital Costs 4 [ Time Frame: Out to 60 days ]
    Change in Hospital Utilization of Renal Replacement Therapy (days on therapy)

  8. Hospital Costs 5 [ Time Frame: Out to 60 days ]
    Change in Hospital Utilization (days hospitalized)


Other Outcome Measures:
  1. Inflammatory mediators in blood [ Time Frame: Out to 14 hours ]
    Changes in inflammatory mediators detected by Immunoassay of Multianalyte Panel - MAP Laboratory Panel of 253 analytes.

  2. Cytokine Sieving Effects [ Time Frame: Out to 8 hours ]
    Change in cytokine levels obtained from plasma and blood collected prior to and after filter. Analyte concentrations in ultrafiltrate and plasma, expressed in the same concentration units, will be aggregated as a ratio of ultrafiltrate concentration to plasma concentration to yield a unitless Sieving Coefficient (SC). SC is an index of membrane function.

  3. Specific Blood Indicators 1 [ Time Frame: Out to 14 hours ]
    Change in blood Ferritin (mg/mL)

  4. Specific Blood Indicators 2 [ Time Frame: Out to 14 hours ]
    Change in blood Interleukin-6 (pg/mL)

  5. Specific Blood Indicators 3 [ Time Frame: Out to 14 hours ]
    Change in blood C-reactive protein (CRP) (mg/L)

  6. Specific Blood Indicators 4 [ Time Frame: Out to 14 hours ]
    Change in blood Lactate Dehydrogenase (LDH) (U/L)

  7. Specific Blood Indicators 5 [ Time Frame: Out to 14 hours ]
    Change in blood D-dimer (mcg/L*FEU2)

  8. Specific Blood Indicators 6 [ Time Frame: Out to 14 hours ]
    Change in blood White Blood Cell (WBC) count (%)

  9. Specific Blood Indicators 7 [ Time Frame: Out to 14 hours ]
    Change in blood Neutrophil count (%)

  10. Specific Blood Indicators 8 [ Time Frame: Out to 14 hours ]
    Change in blood lymphocyte count (%).

  11. Hospital Acquired Infections (HAI) /Sepsis [ Time Frame: 30 and 60 days ]
    Change in the duration of days of diagnosed HAI/ Sepsis infections

  12. Composite Recovery [ Time Frame: Up to 30 days ]
    Duration without Respiratory Replacement Therapy (RRT), ventilator, and time to discharge

  13. Composite Survival [ Time Frame: 30 and 60 days ]
    Survival without Respiratory Replacement Therapy (RRT), ventilator, or time to Long Term Care (LTC)

  14. Composite Non-Recovery [ Time Frame: Up to 60 days ]
    Survival with Respiratory Replacement Therapy (RRT), ventilator or in Long Term Care (LTC)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A patient, or legal authorized representative (LAR), has provided informed consent and a written informed consent form.
  • Positive COVID-19 test.
  • Must be receiving medical care in an intensive care nursing situation.
  • Respiratory failure due to COVID-19 disease requiring invasive mechanical ventilation. This care may include but is not required to include the use of dexamethasone.
  • Within 18 hours of tracheal intubation to support invasive mechanical ventilation. A goal of this study is that T0 will occur within 24 hours of tracheal intubation to support invasive mechanical ventilation.
  • Age 18 to 80 years.
  • Males and females (females of childbearing potential who are not pregnant confirmed by a negative serum pregnancy test) and not lactating if recently post-partum).
  • Intent to deliver full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours.

Exclusion Criteria:

  • Cardiovascular instability that precludes initiation of hemofiltration.
  • Irreversible brain damage based on available historical and clinical information.
  • Presence of any solid organ transplant at any time.
  • Patients with stem cell transplant in the previous 100 days or who have not engrafted.
  • Acute or chronic use of circulatory support device such as extracorporeal membrane oxygenation (ECMO), left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), biventricular assist devices (BIVADs).
  • Metastatic malignancy which is actively being treated or may be treated with chemotherapy or radiation during the subsequent three-month period after study treatment.
  • Chronic immunosuppression defined as use of any immunosuppressant medications (cyclophosphamide, azathioprine, methotrexate, rituximab, mycophenolate, cyclosporine); prednisone use is excepted.
  • Patient is moribund or chronically debilitated for whom full supportive care is not indicated.
  • Concurrent enrollment in another interventional clinical trial except trials of COVID-19 convalescent plasma, anti-severe acute respiratory syndrome (SARS)-CoV2 monoclonal antibodies, or RemdesivirTM. Patients enrolled in observational studies (without the use of an investigative device or drug), are allowed to participate. Any communication between the Principal Investigator (PI) of this Protocol and the PI of any other clinical study will include the Medical Director of the Sponsor; all such correspondence will be documented.
  • Any reason the Investigator deems exclusionary
Layout table for additonal information
Responsible Party: SeaStar Medical
ClinicalTrials.gov Identifier: NCT04537975    
Other Study ID Numbers: CP-01-004
First Posted: September 3, 2020    Key Record Dates
Last Update Posted: December 14, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Edema
Lung Diseases
Respiratory Tract Diseases